BACKGROUND: Thymic stromal lymphopoietin (TSLP) is expressed at sites of allergic inflammation, including eczematous skin. This cytokine has been reported to exert its T(H)2-inducing properties through dendritic cells. Expression of TSLP receptor on the surface of activated T(H)2 cells could amplify T(H)2 responses at inflamed sites through the direct actions of TSLP. OBJECTIVE: To test rigorously whether T(H)2 cells induced by "proallergic" factors express TSLP receptor and characterize these cells using an experimental platform that combines flow cytometry with microscopic capabilities. METHODS: CD4(+) T cells isolated from patients with atopic dermatitis or normal healthy controls were cocultured with autologous dendritic cells in the presence of T(H)2-promoting stimuli (TSLP ± allergen and staphylococcal enterotoxin B ± TSLP). Surface expression of TSLP receptor was analyzed by image-based flow cytometry, and responsiveness of purified T cells to TSLP was assessed by phosphorylation of signal transducer and activator of transcription-5 and cytokine secretion. RESULTS: T(H)2-promoting stimuli induced a robust population of activated T(H)2 cells (CD25(+)IL-4(+)). Regardless of the nature of the stimulus, flow cytometry imaging confirmed that T cells expressing TSLP receptor were rare, constituting a minor fraction of the IL-4(+) T cell pool; however, TSLP responsiveness was nonetheless detectable. Analysis of cell size and nuclear morphology revealed preferential expression of TSLP receptor on IL-4-expressing cells undergoing mitosis. Analysis of lesional skin in atopic dermatitis supported the view that rare IL-4(+) T cells expressing TSLP receptor are present at inflamed sites. CONCLUSION: In a "proallergic" milieu, TSLP receptor is preferentially expressed on rare actively dividing T(H)2 cells. The direct action of TSLP on T cells could amplify T(H)2 responses at sites of allergic inflammation.
BACKGROUND:Thymic stromal lymphopoietin (TSLP) is expressed at sites of allergic inflammation, including eczematous skin. This cytokine has been reported to exert its T(H)2-inducing properties through dendritic cells. Expression of TSLP receptor on the surface of activated T(H)2 cells could amplify T(H)2 responses at inflamed sites through the direct actions of TSLP. OBJECTIVE: To test rigorously whether T(H)2 cells induced by "proallergic" factors express TSLP receptor and characterize these cells using an experimental platform that combines flow cytometry with microscopic capabilities. METHODS:CD4(+) T cells isolated from patients with atopic dermatitis or normal healthy controls were cocultured with autologous dendritic cells in the presence of T(H)2-promoting stimuli (TSLP ± allergen and staphylococcal enterotoxin B ± TSLP). Surface expression of TSLP receptor was analyzed by image-based flow cytometry, and responsiveness of purified T cells to TSLP was assessed by phosphorylation of signal transducer and activator of transcription-5 and cytokine secretion. RESULTS: T(H)2-promoting stimuli induced a robust population of activated T(H)2 cells (CD25(+)IL-4(+)). Regardless of the nature of the stimulus, flow cytometry imaging confirmed that T cells expressing TSLP receptor were rare, constituting a minor fraction of the IL-4(+) T cell pool; however, TSLP responsiveness was nonetheless detectable. Analysis of cell size and nuclear morphology revealed preferential expression of TSLP receptor on IL-4-expressing cells undergoing mitosis. Analysis of lesional skin in atopic dermatitis supported the view that rare IL-4(+) T cells expressing TSLP receptor are present at inflamed sites. CONCLUSION: In a "proallergic" milieu, TSLP receptor is preferentially expressed on rare actively dividing T(H)2 cells. The direct action of TSLP on T cells could amplify T(H)2 responses at sites of allergic inflammation.
Authors: Thaddeus C George; David A Basiji; Brian E Hall; David H Lynch; William E Ortyn; David J Perry; Michael J Seo; Cathleen A Zimmerman; Philip J Morrissey Journal: Cytometry A Date: 2004-06 Impact factor: 4.355
Authors: A Pandey; K Ozaki; H Baumann; S D Levin; A Puel; A G Farr; S F Ziegler; W J Leonard; H F Lodish Journal: Nat Immunol Date: 2000-07 Impact factor: 25.606
Authors: S Ebner; G Ratzinger; B Krösbacher; M Schmuth; A Weiss; D Reider; R A Kroczek; M Herold; C Heufler; P Fritsch; N Romani Journal: J Immunol Date: 2001-01-01 Impact factor: 5.422
Authors: Vassili Soumelis; Pedro A Reche; Holger Kanzler; Wei Yuan; Gina Edward; Bernhart Homey; Michel Gilliet; Steve Ho; Svetlana Antonenko; Annti Lauerma; Kathleen Smith; Daniel Gorman; Sandra Zurawski; Jon Abrams; Satish Menon; Terri McClanahan; Rene de Waal-Malefyt Rd; Fernando Bazan; Robert A Kastelein; Yong-Jun Liu Journal: Nat Immunol Date: 2002-06-10 Impact factor: 25.606
Authors: L S Park; U Martin; K Garka; B Gliniak; J P Di Santo; W Muller; D A Largaespada; N G Copeland; N A Jenkins; A G Farr; S F Ziegler; P J Morrissey; R Paxton; J E Sims Journal: J Exp Med Date: 2000-09-04 Impact factor: 14.307
Authors: Kathryn E Hulse; Amanda J Reefer; Victor H Engelhard; James T Patrie; Steven F Ziegler; Martin D Chapman; Judith A Woodfolk Journal: J Allergy Clin Immunol Date: 2010-01 Impact factor: 10.793
Authors: Jane Yoo; Miyuki Omori; Dora Gyarmati; Baohua Zhou; Theingi Aye; Avery Brewer; Michael R Comeau; Daniel J Campbell; Steven F Ziegler Journal: J Exp Med Date: 2005-08-15 Impact factor: 14.307